MannKind wins US backing for inhaled insulin on years of work | Mint
Sanofi in $150m deal to commercialise Mannkind's inhaled insulin
Mannkind looks to Sanofi for secondary supply of inhalable insulin API
Talking to Your Doctor About Inhaled Insulin
Future of Afrezza Inhaled Insulin: Interview with Michael Castagna, CCO of MannKind Corp. | Medgadget
Sanofi cuts $925m deal for MannKind's inhaled insulin - PMLiVE
MannKind Announces First Patient Enrolled In Inhale-1 Study Of Afrezza® In Pediatric Population
Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis - The Lancet Diabetes & Endocrinology
Sanofi and MannKind announce global licensing agreement for Afrezza® ( insulin human) rapid-acting inhaled insulin - Drug Target Review
MannKind combines inhaled insulin with One Drop's digital diabetes tech - Drug Delivery Business
Sanofi Terminates Partnership for MannKind's Inhaled Insulin, Afrezza
Mannkind's inhaled insulin clears big hurdle
PULMONARY DELIVERY - Afrezza – Another Lesson for Drug Delivery Professionals?
MannKind signs sale-leaseback agreement for inhaled insulin manufacturing site
Cipla partners with MannKind to distribute inhaled insulin | The Financial Express
NRx Pharmaceuticals Partners with MannKind Corporation to Develop ZYESAMITM (aviptadil) Inhaler for Respiratory Conditions – Delco Times
MannKind Explodes Deal With Sanofi
What? MannKind posts best-ever quarter of inhaled-insulin sales - STAT
Sanofi abandons inhaled insulin pact with Mannkind - PMLiVE
![Diabetes without fear - Diabetes sem medo - Afrezza (human insulin [recombinant DNA origin]; (MannKind Corporation, Valencia, California, USA) is a drug-device combination consisting of pre-metered, single-use cartridges of TI inhalation powder](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1395445637138116 "Diabetes without fear - Diabetes sem medo - Afrezza (human insulin [recombinant DNA origin]; (MannKind Corporation, Valencia, California, USA) is a drug-device combination consisting of pre-metered, single-use cartridges of TI inhalation powder")
Diabetes without fear - Diabetes sem medo - Afrezza (human insulin [recombinant DNA origin]; (MannKind Corporation, Valencia, California, USA) is a drug-device combination consisting of pre-metered, single-use cartridges of TI inhalation powder
The AFREZZA® (MannKind Corporation, Valencia, CA, USA): a second... | Download Scientific Diagram
Danbury's MannKind delivers inhalable insulin - Westfair Communications
New form of insulin can be inhaled rather tha | EurekAlert!
Using Inhaled Insulin with Type 1 + Type 2 Diabetes
